Linked Life Data

17034294

Source:http://linkedlifedata.com/resource/pubmed/id/17034294

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-10-12
pubmed:abstractText
Lymphangioleiomyomatosis (LAM) is a rare destructive lung disease characterized by an abnormal proliferation of smooth muscle-like cells (LAM cells) in the lung and along the axial lymphatics. LAM demonstrates a heterogeneous clinical course, but there is no serum surrogate marker available for assessing the disease severity or predicting the disease progression. Since the authors have recently demonstrated the extensive LAM-associated lymphangiogenesis and its potential role in progression and metastasis of LAM cells, they hypothesized that serum levels of lymphangiogenic growth factors might be increased in LAM and become a surrogate marker for disease severity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1539-6851
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
143-52
pubmed:dateRevised
2007-5-2
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
pubmed:affiliation
Department of Respiratory Medicine, Juntendo University, School of Medicine, and Pneumothorax Center, Nissan Tamagawa Hospital, Tokyo, Japan. kseyama@med.juntendo.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't